文献速递神经核医学肿瘤 PET/CT

基于2016 WHO分类重新评估11C-蛋氨酸PET/CT对脑胶质瘤的诊断效能

Re-evaluation of the diagnostic performance of 11C-methionine PET/CT according to the 2016 WHO classification of cerebral gliomas.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-05-17

本研究纳入144例术前接受11C-蛋氨酸(MET)PET/CT的脑胶质瘤患者,按2016 WHO分类分析MET肿瘤/对侧皮层比值(TNR)与IDH1突变及1p/19q共缺失的关系。结果显示IDH1突变型肿瘤MET摄取低于野生型,少突胶质瘤TNR较高,MET摄取对IDH1野生型肿瘤的分级一致性更好。

要点

  • IDH1突变型胶质瘤MET TNR中位数为1.95,野生型为3.35。
  • IDH1突变型中少突胶质瘤TNR中位数2.90,高于星形细胞肿瘤1.40(P<0.001)。
  • IDH1野生型肿瘤低级别与高级别鉴别的AUC为0.976,高于全部肿瘤0.852(P<0.001)。

核心结论

  • IDH1突变型肿瘤MET摄取低于IDH1野生型肿瘤。
  • 无论IDH1突变状态,伴1p/19q共缺失的少突胶质瘤MET摄取可高达高级别IDH1野生型肿瘤水平。
  • MET摄取用于胶质瘤分级在IDH1野生型肿瘤中比IDH1突变型肿瘤更一致。

研究设计与样本

  • 回顾性分析144例术前接受MET PET/CT的脑胶质瘤患者,按2016 WHO分类评估。
  • 计算肿瘤最大SUV与对侧皮层平均SUV的比值(MET TNR)。

主要发现

  • IDH1突变型和野生型肿瘤的中位MET TNR分别为1.95和3.35。
  • 74例IDH1突变型肿瘤中,少突胶质瘤中位MET TNR为2.90,星形细胞肿瘤为1.40(P<0.001)。
  • IDH1突变型星形细胞肿瘤II、III、IV级中位MET TNR分别为1.20、2.05、2.20(II vs III P<0.0001;II vs IV P=0.023)。
  • 少突胶质瘤II级MET TNR低于III级(2.30 vs 3.30,P=0.008)。
  • 鉴别低级别(II级)与高级别(III和IV级)胶质瘤的ROC分析中,野生型肿瘤AUC为0.976,高于全部肿瘤0.852(P<0.001)和IDH1突变型肿瘤0.817(P=0.004)。

关键数值与推荐

  • MET TNR计算公式为肿瘤最大SUV与对侧皮层平均SUV的比值。
  • IDH1突变型少突胶质瘤与星形细胞肿瘤中位MET TNR比较P<0.001。
  • IDH1突变型星形细胞肿瘤II vs III级P<0.0001,II vs IV级P=0.023。
  • 少突胶质瘤II vs III级MET TNR比较P=0.008。
  • 野生型肿瘤AUC 0.976 vs 全部肿瘤0.852 P<0.001,vs IDH1突变型0.817 P=0.004。

临床怎么用

  • 解读MET PET/CT用于胶质瘤分级时需结合IDH1突变状态和1p/19q共缺失状态。
  • IDH1野生型肿瘤中MET TNR对低级别与高级别鉴别效能较高。
  • IDH1突变型少突胶质瘤MET摄取可较高,不宜单独依据MET摄取判断为高级别。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We evaluated the usefulness of 11C-methionine (MET) positron emission tomography/computed tomography (PET/CT) for grading cerebral gliomas according to the 2016 WHO classification with special emphasis on the presence of the isocitrate dehydrogenase 1 (IDH1) gene mutation and 1p/19q codeletion. METHODS: In total, 144 patients underwent MET PET/CT before surgery. The ratios of the maximum standardized uptake value (SUV) of the gliomas to the mean SUV of the contralateral cortex on MET PET/CT (MET TNR) were calculated. RESULTS: The median MET TNRs in IDH1-mutant and IDH1-wildtype tumours were 1.95 and 3.35, respectively. From among 74 IDH1-mutant tumours, the oligodendrogliomas showed a higher median MET TNR than the astrocytic tumours (2.90 vs. 1.40, P < 0.001). In grade II, III and IV IDH1-mutant astrocytic tumours, the median MET TNRs were 1.20, 2.05 and 2.20, respectively (grade II vs. grade III, P < 0.0001; grade II vs. grade IV, P = 0.023). In oligodendrogliomas, the MET TNR was lower fin grade II tumours than in grade III tumours (2.30 vs. 3.30 P = 0.008). In differentiating low-grade (grade II) from high-grade (grade III and IV) gliomas, receiver operating characteristic analysis showed a higher area under the curve for wildtype tumours (0.976) than for all tumours (0.852; P < 0.001) and IDH1-mutant tumours (0.817; P = 0.004). CONCLUSION: IDH1-mutant tumours showed lower MET uptake than IDH1-wildtype tumours. Regardless of IDH1 mutation status, oligodendrogliomas with 1p/19q codeletion showed MET uptake as high as that in high-grade IDH1-wildtype tumours. Therefore, MET uptake for glioma grading was more consistent for IDH1-wildtype tumours than for IDH1-mutant tumours.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Kim D, Chun JH, Kim SH, et al. Re-evaluation of the diagnostic performance of 11C-methionine PET/CT according to the 2016 WHO classification of cerebral gliomas. Eur J Nucl Med Mol Imaging. 2019. PMID: 31102001. doi:10.1007/s00259-019-04337-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。